ZURICH (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling ...

Researchers in Zurich can now verify the statics of railway bridges using a new, specially developed artificial intelligence model.

Samsung Bioepis has now allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

The Sandoz Family Foundation, Novartis's second-largest shareholder with a 4.1% stake, has announced plans to sell a substantial portion of its holdings in the pharmaceutical giant. This strategic ...

Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss ...

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...

More than 60 years of work by local artist Dave Nixon is exhibited in the Mari Sandoz High Plains Heritage Center.

A look ahead at exciting HS updates to be presented at AAD, including emerging therapies, new clinical insights, and procedural advancements.

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

Does the EU’s pharma patent system balance innovation and access—or block competition? Join POLITICO’s Oxford-style debate as ...